ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc.

LEAD PLAINTIFF DEADLINE IS MARCH 19, 2024

NEW YORK, Jan. 26, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit has been filed against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR). The class action, filed in the United States District Court for the District of Massachusetts+, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AlloVir securities between March 22, 2022 and December 21, 2023, both dates inclusive (the "Class Period").

All   investors who purchased shares. and incurred losses are urged to contact the firm immediately at [e-mail] or [phone] or [phone]. You may obtain additional information concerning the action or join the case on our website, www.whafh.com.

AlloVir, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases.

In March 2022, AlloVir initiated global phase 3 registrational studies of its lead product posoleucel for the prevention of life-threatening viral infections from viruses in high-risk, allogeneic hematopoietic cell transplant patients (the "posoleucel Phase 3 Studies").

On December 22, 2023, AlloVir announced that it was discontinuing the posoleucel Phase 3 studies over efficacy concerns and stated that it would explore strategic alternatives for the Company. Specifically, AlloVir said it was discontinuing the posoleucel Phase 3 studies after pre-planned analyses concluded they wouldn't meet their primary endpoints.

On this news, AlloVir's stock price fell $1.57 per share, or 67.38%, to close at $0.76 per share on December 22, 2023.

If you have incurred losses in the shares of AlloVir, you may, no later than March 19, 2024, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of shares of AlloVir, Inc.

PLEASE CLICK THIS LINK TO JOIN THIS CASE

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas, and offices in New York, Chicago, and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at [phone], via e-mail at [e-mail], or visit our website at  www.whafh.com.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [e-mail] or [e-mail]
Tel: [phone] or [phone]

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/allovir-inc-class-action-alert-wolf-haldenstein-adler-freeman--herz-llp-announces-that-a-class--action--lawsuit--has--been--filed--in--the-united-states-district-court-for-the-district-of-massachusetts-against-allovir-inc-302045651.html

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP